{
    "nctId": "NCT06097156",
    "briefTitle": "Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications",
    "officialTitle": "Feasibility Evaluation of See.d Pre-Analytical Platform Performance: From Whole Blood to Plasma and SBS Slides for Liquid Biopsy Applications",
    "overallStatus": "RECRUITING",
    "conditions": "Healthy Participants, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "Evaluation of White Blood Cells adhered on SBS slides",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* General (all participants)\n\n  * Participants is willing and able to give and sign a written informed consent\n  * Aged 18 or above\n  * Blood parameters if available (hematology: complete blood count, kidney and liver function, total protein and albumin, coagulation, etc)\n* Specific for metastatic breast cancer patients\n\n  * Female for metastatic breast cancer patients, aged 18 or above\n  * Histological confirmation of breast cancer\n  * Presence of at least one non-bone metastasis\n  * Disease assessed to be in clinical or radiologic progression to the last line of treatment, as evaluated by the investigator and reported in the CaseReport Form\n  * The biopsy can be scheduled for \\<4 weeks after the date of blood withdrawal\n  * Blood sampling must be performed at least later than 7 days after the last biopsy or any other minor surgical procedure\n* Specific for healthy participants\n\n  * Both sexes for healthy volunteers, aged 18 or above\n  * Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer).\n\nExclusion Criteria:\n\n* Ongoing infections requiring antibiotic or antiviral treatment\n* History of other malignancies other than breast cancer (for healthy participants also includes breast cancer).\n* Undergone major surgery or treatment for breast cancer (including endocrine, targeted, radio- or chemotherapy) \\<4 weeks before enrolment\n* Presence of known severe coagulation or haematological disorder\n* Pregnancy\n* For metastatic breast cancer patients: histological confirmation of a Triple Negative Breast Cancer (TNBC)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}